Report Detail

Global amyotrophic lateral sclerosis treatment market will reach $762.3 million by 2027, growing by 5.8% annually over 2020-2027 owing to the increasing geriatric population worldwide coupled with growing prevalence rate of ALS, and the increase in R&D for new amyotrophic lateral sclerosis therapies.
Highlighted with 80 tables and 67 figures, this 139-page report “Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Region: Trend Outlook and Growth Opportunity” is based on a comprehensive research of the entire global amyotrophic lateral sclerosis treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2017-2019 and provides estimate for 2020 and forecast from 2021 till 2027 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global amyotrophic lateral sclerosis treatment market in every aspect of the classification from perspectives of Treatment Type, ALS Type, Distribution Channel, and Region.

Based on Treatment Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Medication
o Riluzole (Rilutek)
o Radicava (Edaravone)
o Tiglutik (Thickened Riluzole)
o Nuedexta
• Stem Cell Therapy
• Other Treatments

Based on ALS Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Sporadic ALS
• Familial ALS

Based on Distribution Channel, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels

Geographically, the following regions together with the listed national/local markets are fully investigated:
• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, Taiwan, and Philippines)
• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Netherlands, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
• North America (U.S., Canada, and Mexico)
• South America (Brazil, Chile, Argentina, Rest of South America)
• MEA (UAE, Saudi Arabia, South Africa)
For each aforementioned region and country, detailed analysis and data for annual revenue ($ mn) are available for 2017-2027. The breakdown of all regional markets by country and split of key national markets by Treatment Type, ALS Type, and Distribution Channel over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Key Players (this may not be a complete list and extra companies can be added upon request):
AB Science SA
Amylyx Pharmaceuticals Inc.
Biogen Inc.
Biohaven Pharmaceutical Holding Co., Ltd.
BrainStorm Cell Limited
Corestem, Inc.
F.Hoffmann-La Roche AG
Ionis Pharmaceuticals, Inc.
Mitsubishi Tanabe Pharma Corporation
Otsuka Pharmaceutical Co., Ltd.
Sun Pharmaceutical Industries Ltd.
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)


1 Introduction 9

  • 1.1 Industry Definition and Research Scope 9
    • 1.1.1 Industry Definition 9
    • 1.1.2 Research Scope 10
  • 1.2 Research Methodology 13
    • 1.2.1 Overview of Market Research Methodology 13
    • 1.2.2 Market Assumption 14
    • 1.2.3 Secondary Data 14
    • 1.2.4 Primary Data 14
    • 1.2.5 Data Filtration and Model Design 15
    • 1.2.6 Market Size/Share Estimation 16
    • 1.2.7 Research Limitations 17
  • 1.3 Executive Summary 18

2 Market Overview and Dynamics 20

  • 2.1 Market Size and Forecast 20
    • 2.1.1 Impact of COVID-19 on World Economy 21
    • 2.1.2 Impact of COVID-19 on the Market 23
  • 2.2 Major Growth Drivers 25
  • 2.3 Market Restraints and Challenges 29
  • 2.4 Emerging Opportunities and Market Trends 32
  • 2.5 Porter’s Fiver Forces Analysis 36

3 Segmentation of Global Market by Treatment Type 40

  • 3.1 Market Overview by Treatment Type 40
  • 3.2 Medication 42
  • 3.3 Stem Cell Therapy 44
  • 3.4 Other Treatments 45

4 Segmentation of Global Market by ALS Type 46

  • 4.1 Market Overview by ALS Type 46
  • 4.2 Sporadic ALS 48
  • 4.3 Familial ALS 49

5 Segmentation of Global Market by Distribution Channel 50

  • 5.1 Market Overview by Distribution Channel 50
  • 5.2 Hospital Pharmacies 52
  • 5.3 Retail Pharmacies 53
  • 5.4 Online Pharmacies 54
  • 5.5 Other Distribution Channels 55

6 Segmentation of Global Market by Region 56

  • 6.1 Geographic Market Overview 2020-2027 56
  • 6.2 North America Market 2020-2027 by Country 60
    • 6.2.1 Overview of North America Market 60
    • 6.2.2 U.S. 63
    • 6.2.3 Canada 66
    • 6.2.4 Mexico 68
  • 6.3 European Market 2020-2027 by Country 70
    • 6.3.1 Overview of European Market 70
    • 6.3.2 UK 73
    • 6.3.3 France 75
    • 6.3.4 Germany 77
    • 6.3.5 Spain 79
    • 6.3.6 Italy 81
    • 6.3.7 Russia 83
    • 6.3.8 Rest of European Market 85
  • 6.4 Asia-Pacific Market 2020-2027 by Country 87
    • 6.4.1 Overview of Asia-Pacific Market 87
    • 6.4.2 China 90
    • 6.4.3 Japan 92
    • 6.4.4 India 95
    • 6.4.5 Australia 97
    • 6.4.6 South Korea 99
    • 6.4.7 Rest of APAC Region 101
  • 6.5 South America Market 2020-2027 by Country 103
    • 6.5.1 Argentina 106
    • 6.5.2 Brazil 108
    • 6.5.3 Chile 110
    • 6.5.4 Rest of South America Market 112
  • 6.6 MEA Market 2020-2027 by Country 113
    • 6.6.1 UAE 116
    • 6.6.2 Saudi Arabia 118
    • 6.6.3 South Africa 120
    • 6.6.4 Other National Markets 122

7 Competitive Landscape 123

  • 7.1 Overview of Key Vendors 123
  • 7.2 New Product Launch, Partnership, Investment, and M&A 126
  • 7.3 Company Profiles 127

AB Science SA 127

    Amylyx Pharmaceuticals Inc. 129

      Biogen Inc. 130

        Biohaven Pharmaceutical Holding Co., Ltd. 131

          BrainStorm Cell Limited 132

            Corestem, Inc. 133

              F.Hoffmann-La Roche AG 134

                Ionis Pharmaceuticals, Inc. 135

                  Mitsubishi Tanabe Pharma Corporation 136

                    Otsuka Pharmaceutical Co., Ltd. 137

                      Sun Pharmaceutical Industries Ltd. 138

                        RELATED REPORTS 139

                        Summary:
                        Get latest Market Research Reports on Amyotrophic Lateral Sclerosis (ALS) Treatment. Industry analysis & Market Report on Amyotrophic Lateral Sclerosis (ALS) Treatment is a syndicated market report, published as Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020-2027 by Treatment Type (Medication, Stem Cell Therapy, Others), ALS Type (Sporadic, Familial), Distribution Channel, and Region: Trend Outlook and Growth Opportunity. It is complete Research Study and Industry Analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                        Last updated on

                        REPORT YOU MIGHT BE INTERESTED

                        Purchase this Report

                        $3,200.00
                        $4,300.00
                        $5,400.00
                        2,534.40
                        3,405.60
                        4,276.80
                        2,956.80
                        3,973.20
                        4,989.60
                        484,128.00
                        650,547.00
                        816,966.00
                        266,784.00
                        358,491.00
                        450,198.00
                        Credit card Logo

                        Related Reports


                        Reason to Buy

                        Request for Sample of this report